TGFB2 and lung cancer: Figure 5B shows the copy number differentials for the high- and low-risk scores, which were amplified in chromosomes 2, 4, 6, 7, 12, and 19, and lost in 3, 5, 9, 19, and 20. Immunohistochemical studies also showed that the expressions of CCNA2 in lung cancer and normal tissues were also different in the human protein atlas database (Figure 5C). The CBioportal database shows that TGFB2’s mutation rate among the lung cancer population was as high as 9% (Figure 5D).